Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up prior to trading on Tuesday . The stock had previously closed at $27.60, but opened at $28.42. Ascentage Pharma Group International shares last traded at $29.26, with a volume of 2,005 shares.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Piper Sandler started coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price target for the company. Oppenheimer started coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price on the stock. Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a research report on Monday, November 24th. Finally, BTIG Research initiated coverage on shares of Ascentage Pharma Group International in a research note on Monday, November 10th. They issued a “buy” rating and a $50.00 target price on the stock. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $48.50.

Ascentage Pharma Group International Trading Down 3.2%

The firm’s 50 day simple moving average is $32.77 and its 200 day simple moving average is $36.74. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

Institutional Trading of Ascentage Pharma Group International

Institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ascentage Pharma Group International during the 3rd quarter valued at $96,000. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International in the third quarter valued at about $204,000. Chevy Chase Trust Holdings LLC bought a new position in shares of Ascentage Pharma Group International during the second quarter valued at about $227,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International during the third quarter worth about $383,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the second quarter worth about $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.